Top

Published in:

01-10-2009 | Brief Report

Pentoxyphylline in association with vitamin E reduces cutaneous fibrosis in systemic sclerosis

Authors: Romy Beatriz Christmann de Souza, André Regis Macedo, Kátia Akemi Kuruma, Patricia Andrade Macedo, Claudia Teresa Lobato Borges

Published in: Clinical Rheumatology | Issue 10/2009

Abstract

Systemic sclerosis (SSc) is a disorder characterized by skin thickness and vasculopathy. The objective of the study was to evaluate the therapeutic effect and safety of the association of pentoxyphylline and vitamin E in SSc patients. Twelve SSc patients (American College of Rheumatology criteria) enrolled this 24-week open-label study. Patients received daily 800 mg of pentoxyphylline and 800 UI of vitamin E and were evaluated at 4-week interval. The primary efficacy endpoint was the change in Modified Rodnan Skin Score (MRSS) at week 24. Nine diffuse SSc patients treated 6 months with cyclophosphamide were used as a historical control group. The mean age of the treated group was 43.6 years, and ten of 12 (84%) patients were women. Their mean MRSS reduced from 25.7 to 18.7 (p = 0.03) at 16th week and remained significantly reduced throughout the study. In contrast, only a trend of MRSS reduction was observed in the historical control group (p = 0.06). Two patients started the study with active ischemic ulcers and ended with a complete healing of them. No serious side effects were reported. Pentoxyphylline and vitamin E might be an alternative therapeutic approach in SSc patients.

Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444PubMedCrossRef

Steen VD, Medsger TA Jr, Rodnan GP (1982) D-penicillamine therapy in progressive systemic sclerosis (scleroderma). Ann Intern Med 97:652–659PubMed

Jimenez SA, Sigal SH (1991) A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J Rheumatol 18:1496–1503PubMed

Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger TA Jr, Steen VD, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Furst DE (2000) Skin thickness score as a predictor and correlate of outcome in systemic sclerosis. Arthritis Rheum 43:2445–2454PubMedCrossRef

Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, Weisman MH, Barr W, Moreland LW, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold JR (1999) High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 42:1194–1203PubMedCrossRef

Furst DE, Clements PJ, Hillis S, Lachenbruch PA, Miller BL, Sterz MG, Paulus HE (1989) Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum 32:584–593PubMedCrossRef

Steen VD (2001) Treatment of systemic sclerosis. Am J Clin Dermatol 2(5):315–325PubMedCrossRef

Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Scleroderma Lung Study Research Group (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655–2666PubMedCrossRef

Bayat M, Chelcheraghi F, Piryaei A, Rakhshan M, Mohseniefar Z, Rezaie F, Bayat M, Shemshadi H, Sadeghi Y, 6 (2006) The effect of 30-day pretreatment with Pentoxyphylline on the survival of a random skin flap in the rat: an ultrastructural and biomechanical evaluation. Med Sci Monit 12(6):BR201–BR207PubMed

10.

Tulsyan N, Ouriel K, Kashyap VS (2006) Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs 11(1):75–90PubMedCrossRef

11.

Delanian S (1998) Striking regression of radiation-induced fibrosis by a combination of Pentoxyphylline and tocopherol. Br J Radiol 71:892–894PubMed

12.

Berman B, Duncan MR (1990) Pentoxyphylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphea skin and their production of collagen, glycosaminoglycans and fibronectin. Br J Dermatol I23:339–346CrossRef

13.

Okunieff P, Augustine E, Hicks JE, Cornelison TL, Altemus RM, Naydich BG, Ding I, Huser AK, Abraham EH, Smith JJ, Coleman N, Gerber LH (2004) Pentoxyphylline in the treatment of radiation-induced fibrosis. J Clin Oncol 22:2207–2213PubMedCrossRef

14.

Hille A, Christiansen H, Pradier O, Hermann RM, Siekmeyer B, Weiss E, Hilgers R, Hess CF, Schmidberger H (2005) Effect of Pentoxyphylline and tocopherol on radiation proctitis/enteritis. Strahlenther Onkol 181:606–614PubMedCrossRef

15.

Delanian S, Porcher R, Rudant J, Lefaix JL (2005) Kinetics of response to long-term treatment combining Pentoxyphylline and tocopherol in patients with superficial radiation-induced fibrosis. J Clin Oncol 23:8570–8579PubMedCrossRef

16.

Boerma M, Roberto KA, Hauer-Jensen M (2008) Prevention and treatment of functional and structural radiation injury in the rat heart by Pentoxyphylline and alpha-tocopherol. Int J Radiat Oncol Biol Phys 72(1):170–177PubMed

17.

Herrick AL, Hollis S, Schofield D, Rieley F, Blann A, Griffin K, Moore T, Braganza JM, Jayson MIV (2000) A double-blind placebo-controlled trial of andioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 18:349–356PubMed

18.

Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI (1994) Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol 21:1477–1483PubMed

19.

Kamimura M (1974) Comparison of alpha-tocopheryl nicotinate and acetate on skin microcirculation. Am J Clin Nutr 27:1110–1116PubMed

20.

Mizutani H, Yoshida T, Nouchi N, Hamanaka H, Shimizu M (1999) Topical tocoretinate improved hypertrophic scar, skin sclerosis in systemic sclerosis and morphea. J Dermatol 26:11–17PubMed

21.

Haidara MA, Khloussy H, Ammar H, Aal Kassem LA (2004) Impact of alpha-tocopherol and vitamin C on endothelial markers in rats with streptozotocin-induced diabetes. Med Sci Monit 10(2):BR41–BR46PubMed

22.

Peerapatdit T, Likidlilid A, Patchanans N, Somkasetrin A (2006) Antioxidant status and lipid peroxidation end products in patients of type 1 diabetes mellitus. J Med Assoc Thai 89(Suppl 5):S141–S146PubMed

23.

Furst DE, Clements PJ, Steen VD, Medsger TA Jr, Masi AT, D'Angelo WA, Lachenbruch PA, Grau RG, Seibold JR (1998) The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 25(1):84–88PubMed

24.

Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23(5):581–590CrossRef

25.

LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202–205PubMed

26.

Samlaska CP, Winfield A (1994) Pentoxyphylline. J Am Acad Dermatol 30:603–621PubMedCrossRef

27.

Leonhardt H, Griofoleti HG (1997) Effects of Pentoxyphylline on red blood cell deformability and blood viscosity under hyperosmolar conditions. Arch Pharmacol 299:197–200CrossRef

28.

Bermand B, Duncan MR (1990) Pentoxyphylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphea skin and their production of collagen, glycosaminoglycans and fibronectin. Br J Dermatol 123:339–346CrossRef

29.

Fischer M, Wohlrab J, Marsch WC (2001) Crux medicorum ulcerated radiation-induced fibrosis- successful therapy with Pentoxyphylline a vitamin E. Eur J Dermatol 11:38–40PubMed

30.

Goodfield MJD, Rowell NR (1989) Treatment of peripheral gangrene due to systemic sclerosis with intravenous Pentoxyphylline. Clin Exp Dermatol 14:161–162PubMedCrossRef

31.

Simonini G, Pignone A, Generini S, Falcini F, Cerinic MM (2000) Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology 155:1–15PubMedCrossRef

32.

Henness S, Wigley FM (2007) Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Curr Opin Rheumatol 19(6):611–618PubMedCrossRef

33.

Gazi H, Pope JE, Clements P, Medsger TA, Martin RW, Merkel PA, Kahaleh B, Wollheim FA, Baron M, Csuka ME, Emery P, Belch JF, Hayat S, Lally EV, Korn JH, Czirjak L, Herrick A, Voskuyl AE, Bruehlmann P, Inanc M, Furst DE, Black C, Ellman MH, Moreland LW, Rothfield NF, Hsu V, Mayes M, McKown KM, Krieg T, Siebold JR (2007) Outcome measurements in scleroderma: results from a Delphi exercise. J Rheumatol 34(3):501–509PubMed

Title: Pentoxyphylline in association with vitamin E reduces cutaneous fibrosis in systemic sclerosis
Authors: Romy Beatriz Christmann de Souza
André Regis Macedo
Kátia Akemi Kuruma
Patricia Andrade Macedo
Claudia Teresa Lobato Borges
Publication date: 01-10-2009
Publisher: Springer-Verlag
Published in: Clinical Rheumatology / Issue 10/2009
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-009-1202-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2009

Persistent low grade synovitis without erosive progression in magnetic resonance imaging of rheumatoid arthritis patients treated with infliximab over 1 year

Syndrome of periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) in siblings

Does a special relationship between personality and rheumatoid arthritis exist? Experiences with an Austrian Psychological Questionnaire

Peripheral bone density in patients with rheumatoid arthritis

Patients’ perceptions of health-related quality of life in rheumatoid arthritis

Glucosamine sulfate—environmental antibacterial activity

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials